https://www.statcounter.com/counter/counter.js
Web Analytics
Home » Posts tagged with » Lung cancer
OncoCyte to acquire Razor Genomics to advance lung cancer diagnosis

OncoCyte to acquire Razor Genomics to advance lung cancer diagnosis

OncoCyte acquisition of Razor Genomics : US diagnostic tests developer OncoCyte has agreed to acquire Razor Genomics, a provider of molecular diagnostic testing services for lung cancer. Initially, the diagnostic tests developer will acquire an initial 25% equity interest in the form of the Razor Genomics’ preferred stock for $10 million. After closing of the […]

Tagrisso FLAURA trial results : AstraZeneca NSCLC drug significantly improves OS

Tagrisso FLAURA trial results : Pharma giant AstraZeneca said that the phase 3 FLAURA trial evaluating Tagrisso (osimertinib) in previously untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) has yielded positive overall survival (OS) results. The randomized, double-blinded, multicenter late-stage trial featured NSCLC patients whose tumors have epidermal growth factor receptor (EGFR) […]

Continue reading …
Ethicon wraps up $3.4bn acquisition of robotic medical company Auris Health

Ethicon acquisition of Auris Health : Johnson & Johnson’s subsidiary Ethicon has wrapped up its previously announced $3.4 billion acquisition of California-based robotic medical company Auris Health. Ethicon acquisition of Auris Health Based on the achievement of certain predetermined milestones, the deal will see additional contingent payments made by Ethicon worth up to $2.35 billion. […]

Continue reading …
Pfizer lung cancer drug Vizimpro bags CHMP’s positive opinion

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Pfizer lung cancer drug Vizimpro (dacomitinib) 45 mg in Europe as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The positive opinion adopted by the European Medicines Agency (EMA) committee is […]

Continue reading …
InventisBio out-licenses lung cancer drug D-0316 to Betta Pharma

InventisBio (Shanghai) has agreed to out-license the rights of its EGFR-T790M tyrosine kinase inhibitor D-0316 in China, Hong Kong and Taiwan to Betta Pharma, in a deal worth more than RMB230 million ($33.44 million). The two Chinese pharma companies have forged a partnership to co-develop the drug in China. D-0316, which was discovered by InventisBio, […]

Continue reading …
CHMP recommends AstraZeneca lung cancer drug Imfinzi EMA approval

Update on Imfinzi EMA approval : The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the approval of AstraZeneca lung cancer drug Imfinzi (durvalumab) for the treatment of locally-advanced, unresectable non-small cell lung cancer (NSCLC). The committee has recommended Imfinzi EMA approval of […]

Continue reading …
AstraZeneca lung cancer drug Tagrisso gets FDA breakthrough therapy designation

Pharma news updates : Tagrisso (osimertinib), the AstraZeneca lung cancer drug has bagged the breakthrough therapy designation (BTD) from the US FDA for the treatment of non-small cell lung cancer (NSCLC) in a first line setting. The BTD designation for the AstraZeneca cancer drug is specifically for treating metastatic NSCLC patients who have tested positive […]

Continue reading …
Men who take vitamin B supplements at greater risk of lung cancer

As per the new study, men who take high doses of vitamin B supplements like Vitamin B6 or B12 are at high risk of getting lung cancer as reported in daily Mail. The B complex vitamins help red blood cells to process proteins, fats and carbohydrate. Vitamin B complex is available in natural foods like […]

Continue reading …
Merck lung cancer drug Keytruda plus chemo gets FDA approval for NSCLC

Merck’s cancer immunotherapy Keytruda (pembrolizumab) in combination with chemotherapy has been approved by the US Food and Drug Administration (FDA) as a first-line option for advanced lung cancer treatment in patients who didn’t take any medicines before for the disease. The Keytruda chemotherapy combination has been approved to treat metastatic non-squamous non small cell lung […]

Continue reading …
Novartis lung cancer drug Zykadia gets US FDA priority review

Swiss pharma Novartis has announced that its lung cancer drug Zykadia (ceritinib) has been granted the FDA priority review for its expanded use as the first-line treatment for lung cancer patients with certain conditions. The expanded use is for metastatic non-small cell lung cancer (NSCLC) patients whose tumors were detected by an approved FDA test […]

Continue reading …
Page 1 of 212